|
1) Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996; 84: 321-30
|
|
|
|
2) Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996; 93: 3444-9
|
|
|
|
|
|
3) Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J. 1995; 14: 341-50
|
|
|
|
|
|
4) Ahn MY, Huang G, Bae SC, et al. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. Proc Natl Acad Sci U S A. 1998; 95: 1812-7
|
|
|
|
|
|
5) Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004; 10: 299-304
|
|
|
|
|
|
6) Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005; 106: 494-504
|
|
|
|
|
|
7) Putz G, Rosner A, Nuesslein I, et al. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene. 2006; 25: 929-39
|
|
|
|
|
|
8) Miyoshi H, Shimizu K, Kozu T, et al. t(8; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991; 88: 10431-4
|
|
|
|
|
|
9) Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2 alpha B gene associated with myeloblastic leukemias. Blood. 1999; 93: 1817-24
|
|
|
|
|
|
10) Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000; 96: 3154-60
|
|
|
|
|
|
11) Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000; 96: 2862-9
|
|
|
|
|
|
12) Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics. 1999; 23: 166-75
|
|
|
|
|
|
13) Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004; 23: 4284-96
|
|
|
|
|
|
14) Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002; 99: 1364-72
|
|
|
|
|
|
15) Matheny CJ, Speck ME, Cushing PR, et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 2007; 26: 1163-75
|
|
|
|
|
|
16) Niini T, Kanerva J, Vettenranta K, et al. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica. 2000; 85: 362-6
|
|
|
|
|
|
17) Wotton S, Stewart M, Blyth K, et al. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res. 2002; 62: 7181-5
|
|
|
|
|
|
18) Yanagida M, Osato M, Yamashita N, et al. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene. 2005; 24: 4477-85
|
|
|
|
|
|
19) Miyoshi H, Ohira M, Shimizu K, et al. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res. 1995; 23: 2762-9
|
|
|
|
|
|
20) Tsuzuki S, Hong D, Gupta R, et al. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med. 2007; 4: e172
|
|
|
|
|
|
21) Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001; 8: 189-91
|
|
|
|
|
|
22) Meyers S, Lenny N, Hiebert SW. The t(8; 21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol. 1995; 15: 1974-82
|
|
|
|
|
|
23) Tanaka T, Mitani K, Kurokawa M, et al. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3; 21) leukemias. Mol Cell Biol. 1995; 15: 2383-92
|
|
|
|
|
|
24) Rhoades KL, Hetherington CJ, Harakawa N, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000; 96: 2108-15
|
|
|
|
|
|
25) Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001; 98: 10398-403
|
|
|
|
|
|
26) Higuchi MO, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8; 21) acute myeloid leukemia. Cancer Cell. 2002; 1: 63-74
|
|
|
|
|
|
27) Schwieger M, Lohler J, Friel J, et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med. 2002; 196: 1227-40
|
|
|
|
|
|
28) de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol. 2002; 22: 5506-17
|
|
|
|
|
|
29) Ichikawa M, Goyama S, Asai T, et al. AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol. 2008; 180: 4402-8
|
|
|
|
|
|
30) Huang G, Zhang P, Hirai H, et al. PU. 1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2008; 40: 51-60
|
|
|
|
|
|
31) Peterson LF, Yan M, Zhang D. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8; 21) fusion protein AML1-ETO. Blood. 2007; 109: 4392-8
|
|
|
|
|
|
32) Linggi B, Muller-Tidow C, van de Locht L, et al. The t(8; 21) fusion protein, AML1/ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002; 8: 743-50
|
|
|
|
|
|
33) Yang G, Khalaf W, van de Locht L, et al. Transcriptional repression of the neurofibromatosis-1 tumor suppressor by the t(8; 21) fusion protein. Mol Cell Biol. 2005; 25: 5869-79
|
|
|
|
|
|
34) Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8; 21) transcript promotes leukemogenesis. Nat Med. 2006; 12: 945-9
|
|
|
|
|
|
35) Takeshita M, Ichikawa M, Nitta E, et al. AML1-Evi-1 specifically transforms hematopoietic stem cells through fusion of the entire Evi-1 sequence to AML1. Leukemia. 2008; 22: 1241-9
|
|
|
|
|
|
36) Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008; 111: 4297-308
|
|
|
|
|
|
37) Motoda L, Osato M, Yamashita N, et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells. 2007; 25: 2976-86
|
|
|
|
|